Keap1 Antibody (333116)

Detection of Keap1 by Western Blot

Effect of RSO on Nrf2-Keap1 pathway of LPS-induced RAW 264.7 cells. Relative mRNA expression of Nrf2 (A), HO-1 (B), NQO1 (C), and Keap1 (D) genes normalized to beta -actin and expressed as fold change of the control group, n = 3. (E) The protein levels of Nrf2 and Keap1 were analyzed by immunoblotting with beta -actin as the internal reference protein for normalization, n = 3. Relative protein expression of Nrf2 (F) and Keap1 (G) were expressed as fold change of the LPS-induced group. ** p < 0.01 vs control group; # p < 0.05, ## p < 0.01 vs LPS-induced group. Image collected and cropped by CiteAb from the following open publication (https://www.mdpi.com/2072-6643/14/7/1349), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Keap1 by Western Blot

MeHg induced the expression of antioxidant enzymes in C8-D1A astrocytic cells. Astrocytic C8-D1A cells were treated with MeHg (0, 0.1, 0.5, 1, 5, 10, or 20 µM). Western blot analysis was used to measure changes in the antioxidant proteins Nrf2 (A), KEAP1 (B), HO-1 (C), and SOD2 (D) in C8-D1A cells exposed to 10 µM MeHg for 30 min, 1, 3, 6, or 24 h. (E) shows representative densitometry images. Hmox1 (F), Nqo1 (G), Sod2 (H), and Slc7a11 (I) gene expression were measured using qPCR in cells exposed to 10 µM MeHg for 1, 3, or 6 h. Data are presented as mean ± SD. Statistical significance was determined using one-way ANOVA followed by Bonferroni’s post-hoc analysis, or with the Kruskal-Wallis test followed by Dunn’s post hoc test, adjusted by Bonferroni correction when normality was not achieved. p < 0.05 was considered statistically significant, * denotes a significant difference Image collected and cropped by CiteAb from the following open publication (https://link.springer.com/10.1007/s11064-025-04507-7), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Keap1 by Western Blot

NRF2 expression is positively associated with malignancy in HNSCC. (A, C, D) Representative IHC staining of NRF2 in the specimens obtained from HNSCC patients. Brown staining indicates NRF2 positivity. The cell nuclei and background were counterstained with hematoxylin (blue coloration). (A) NRF2 protein expression in HNSCC specimens with different clinicopathological stages. Magnification, 100× (upper panel) and 400× (lower panel). (B) The correlation between the level of nuclear and cytosolic expression of NRF2 and tumor stage was estimated using the immunoreactivity scoring system (IRS). The IRS was calculated by multiplying the intensity of NRF2 staining (scale, 0-3) by the percentage of positive cells (4, > 80%; 3, 51-80%; 2, 10-50%; 1, < 10%; 0, 0%), which resulted in values ranging from 0 to 12. Groups with different letters are significant different (p < 0.05) from each other. (C) NRF2 protein expression was positively correlated with the degree of tumor cell differentiation in human head and neck squamous cell carcinoma. Magnification, 50× (upper panel) and 400× (lower panel). (D) NRF2 expression was highest in the invasive carcinoma nests. Magnification 50×. (E) Levels of NRF2 and NRF2 downstream targets in dysplasia oral keratinocyte (DOK) and HNSCC cell lines. (F) Motility of DOK and various HNSCC cell lines via trans-well migration assay. * p < 0.05; ** p < 0.01; *** p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33859744), licensed under a CC-BY license. Not internally tested by R&D Systems.